In patients diagnosed with type 2 diabetes through screening in general practice, intensive multifactorial treatment improved cardiovascular risk factors, compared with usual care, new findings suggest, but those improvements were very small.…

Higher levels of vitamin D in the blood appear to be associated with a reduced risk for incident diabetes among people at high risk for the disease.…

Takeda Pharmaceuticals recently completed a Phase 2 study with its novel anti-diabetic agent TAK-875, which could help lead to more individualized patient care and diabetes management….

The vascular endothelial growth factor (VEGF) inhibitor ranibizumab (Lucentis) proves promising in treating diabetic macular edema….

Steve and Andrew came home with tons of new information from the recent ADA 71st Scientific Sessions. We are going to be sharing the information with you for the next couple of weeks as we continue to review and evaluate the articles and studies. There are articles on new classes …

Americans are well informed about the risks, dangers, and signs of diabetes, but that knowledge does not appear to translate into actions to prevent or control the disease, researchers reported. Almost 87% of the 3,867 type 2 diabetes respondents in a huge national sampling knew that obesity contributes to chronic …

A matchstick-sized implantable subcutaneous pump that delivers a steady flow of the GLP-1 agonist exenatide (Byetta) maintained improvements in glycemic control over a year, researchers said. The purpose is to increase adherence, while offering greater efficacy and reduced side effects. The pump has to be inserted every three months, but …

NC-stat — DPNCheck Fast, accurate and quantitative test that may be used to evaluate peripheral neuropathies such as DPN. It may aid in the early detection, confirmation, and monitoring of DPN. It measures sural nerve conduction velocity – a standard biomarker for subclinical and symptomatic DPN. It is sensitive and specific for …

We asked our readers to give us feedback into how much they knew about GLP-1 Analogs and a broad cross-section replied. Take a look at 5 of the questions and how your colleagues answered…. It appears that most of you knew that a large amount of GLP-1 production is lost …

Steve and Andrew came back with a ton of new data on GLP-1 Agonist therapies from the 71st Scientific Sessions of the ADA. We turned over these articles, abstracts, posters and presentations to our interns for them to get down to what really matters. They have three articles focusing on …